Natural Killer Cells Occupy Unique Spatial Neighborhoods in HER2 and HER2 Human Breast Cancers

Overview

Journal Breast Cancer Res

Date 2025 Jan 25

PMID 39856748

Authors

Femke A I Ehlers

Katie E Blise

Courtney B Betts

Shamilene Sivagnanam

Loes F S Kooreman

E Shelley Hwang

Gerard M J Bos

Lotte Wieten

Lisa M Coussens

Affiliations

Soon will be listed here.

Abstract

Tumor-infiltrating lymphocytes are considered clinically beneficial in breast cancer, but the significance of natural killer (NK) cells is less well characterized. As increasing evidence has demonstrated that the spatial organization of immune cells in tumor microenvironments is a significant parameter for impacting disease progression as well as therapeutic responses, an improved understanding of tumor-infiltrating NK cells and their location within tumor contextures is needed to improve the design of effective NK cell-based therapies. In this study, we developed a multiplex immunohistochemistry (mIHC) antibody panel designed to quantitatively interrogate leukocyte lineages, focusing on NK cells and their phenotypes, in two independent breast cancer patient cohorts (n = 26 and n = 30). Owing to the clinical evidence supporting a significant role for NK cells in HER2 breast cancer in mediating responses to Trastuzumab, we further evaluated HER2 and HER2 specimens separately. Consistent with literature, we found that CD3 T cells were the dominant leukocyte subset across breast cancer specimens. In comparison, NK cells, identified by CD56 or NKp46 expression, were scarce in all specimens with low granzyme B expression indicating reduced cytotoxic functionality. Whereas NK cell density and phenotype did not appear to be influenced by HER2 status, spatial analysis revealed distinct NK cells phenotypes regarding their proximity to neoplastic tumor cells that associated with HER2 status. Spatial cellular neighborhood analysis revealed multiple unique neighborhood compositions surrounding NK cells, where NK cells from HER2 tumors were more frequently found proximal to neoplastic tumor cells, whereas NK cells from HER2 tumors were instead more frequently found proximal to CD3 T cells. This study establishes the utility of quantitative mIHC to evaluate NK cells at the single-cell spatial proteomics level and illustrates how spatial characteristics of NK cell neighborhoods vary within the context of HER2 and HER2 breast cancers.

References

Stankovic B, Bjorhovde H, Skarshaug R, Aamodt H, Frafjord A, Muller E . Immune Cell Composition in Human Non-small Cell Lung Cancer. Front Immunol. 2019; 9:3101. PMC: 6367276. DOI: 10.3389/fimmu.2018.03101. View

Bryceson Y, March M, Ljunggren H, Long E . Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion. Blood. 2005; 107(1):159-66. PMC: 1895346. DOI: 10.1182/blood-2005-04-1351. View

Kim R, Kawai A, Wakisaka M, Sawada S, Shimoyama M, Yasuda N . Immune correlates of the differing pathological and therapeutic effects of neoadjuvant chemotherapy in breast cancer. Eur J Surg Oncol. 2019; 46(1):77-84. DOI: 10.1016/j.ejso.2019.09.146. View

Muntasell A, Rojo F, Servitja S, Rubio-Perez C, Cabo M, Tamborero D . NK Cell Infiltrates and HLA Class I Expression in Primary HER2 Breast Cancer Predict and Uncouple Pathological Response and Disease-free Survival. Clin Cancer Res. 2018; 25(5):1535-1545. DOI: 10.1158/1078-0432.CCR-18-2365. View

Mahgoub S, Abosalem H, Emara M, Kotb N, Maged A, Soror S . Restoring NK cells functionality via cytokine activation enhances cetuximab-mediated NK-cell ADCC: A promising therapeutic tool for HCC patients. Mol Immunol. 2021; 137:221-227. DOI: 10.1016/j.molimm.2021.07.008. View

Garcia-Iglesias T, Del Toro-Arreola A, Albarran-Somoza B, Del Toro-Arreola S, Sanchez-Hernandez P, Ramirez-Duenas M . Low NKp30, NKp46 and NKG2D expression and reduced cytotoxic activity on NK cells in cervical cancer and precursor lesions. BMC Cancer. 2009; 9:186. PMC: 2704222. DOI: 10.1186/1471-2407-9-186. View

Carrega P, Morandi B, Costa R, Frumento G, Forte G, Altavilla G . Natural killer cells infiltrating human nonsmall-cell lung cancer are enriched in CD56 bright CD16(-) cells and display an impaired capability to kill tumor cells. Cancer. 2008; 112(4):863-75. DOI: 10.1002/cncr.23239. View

Tagaya H, Ishikawa K, Hosokawa Y, Kobayashi S, Ueoka Y, Shimada M . A method of producing genetically manipulated mouse mammary gland. Breast Cancer Res. 2019; 21(1):1. PMC: 6321679. DOI: 10.1186/s13058-018-1086-8. View

Arnould L, Gelly M, Penault-Llorca F, Benoit L, Bonnetain F, Migeon C . Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?. Br J Cancer. 2006; 94(2):259-67. PMC: 2361112. DOI: 10.1038/sj.bjc.6602930. View

Schmidt L, Eskiocak B, Kohn R, Dang C, Joshi N, DuPage M . Enhanced adaptive immune responses in lung adenocarcinoma through natural killer cell stimulation. Proc Natl Acad Sci U S A. 2019; 116(35):17460-17469. PMC: 6717259. DOI: 10.1073/pnas.1904253116. View

10.

Sorrelle N, Ganguly D, Dominguez A, Zhang Y, Huang H, Dahal L . Improved Multiplex Immunohistochemistry for Immune Microenvironment Evaluation of Mouse Formalin-Fixed, Paraffin-Embedded Tissues. J Immunol. 2018; 202(1):292-299. PMC: 6310091. DOI: 10.4049/jimmunol.1800878. View

11.

McNamara K, Caswell-Jin J, Joshi R, Ma Z, Kotler E, Bean G . Spatial proteomic characterization of HER2-positive breast tumors through neoadjuvant therapy predicts response. Nat Cancer. 2021; 2(4):400-413. PMC: 8713949. DOI: 10.1038/s43018-021-00190-z. View

12.

Li Y, Hu C, Shao Q, Huang M, Hou J, Xie D . Elevated expressions of survivin and VEGF protein are strong independent predictors of survival in advanced nasopharyngeal carcinoma. J Transl Med. 2008; 6:1. PMC: 2254380. DOI: 10.1186/1479-5876-6-1. View

12.

Muntasell A, Servitja S, Cabo M, Bermejo B, Perez-Buira S, Rojo F . High Numbers of Circulating CD57 NK Cells Associate with Resistance to HER2-Specific Therapeutic Antibodies in HER2 Primary Breast Cancer. Cancer Immunol Res. 2019; 7(8):1280-1292. DOI: 10.1158/2326-6066.CIR-18-0896. View

13.

Clynes R, Towers T, Presta L, Ravetch J . Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med. 2000; 6(4):443-6. DOI: 10.1038/74704. View

14.

Chretien A, Devillier R, Granjeaud S, Cordier C, Demerle C, Salem N . High-dimensional mass cytometry analysis of NK cell alterations in AML identifies a subgroup with adverse clinical outcome. Proc Natl Acad Sci U S A. 2021; 118(22). PMC: 8179170. DOI: 10.1073/pnas.2020459118. View

15.

Park Y, Lal S, Lee J, Choi Y, Wen J, Ram S . Chemotherapy induces dynamic immune responses in breast cancers that impact treatment outcome. Nat Commun. 2020; 11(1):6175. PMC: 7710739. DOI: 10.1038/s41467-020-19933-0. View

16.

Bouzidi L, Triki H, Charfi S, Ben Kridis W, Derbel M, Ayadi L . Prognostic Value of Natural Killer Cells Besides Tumor-Infiltrating Lymphocytes in Breast Cancer Tissues. Clin Breast Cancer. 2021; 21(6):e738-e747. DOI: 10.1016/j.clbc.2021.02.003. View

17.

Myers J, Miller J . Exploring the NK cell platform for cancer immunotherapy. Nat Rev Clin Oncol. 2020; 18(2):85-100. PMC: 8316981. DOI: 10.1038/s41571-020-0426-7. View

18.

Johnson B, Creason A, Stommel J, Keck J, Parmar S, Betts C . An omic and multidimensional spatial atlas from serial biopsies of an evolving metastatic breast cancer. Cell Rep Med. 2022; 3(2):100525. PMC: 8861971. DOI: 10.1016/j.xcrm.2022.100525. View